Grail, Inc. (GRAL) Stock Forecast Nov. 4, 2026
Analysis updated on Nov. 4, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Grail, Inc. (GRAL) stock forecast summary
Our AI scores Grail, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Grail, Inc. is a mid-cap company with a market capitalization of $6.23B. It ranks number 6 by market capitalization among the 26 Services-Medical Laboratories issuers in our coverage with a current forecast.
For GRAL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -45.0%, measured on 254 forecast dates between 2024-08-14 and 2026-08-06 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -24.0%, measured on 296 forecast dates between 2024-08-14 and 2026-10-05. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.3%, sell < +1.7%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, GRAL included.
GRAL price chart and AI forecast
How GRAL ranks among 4891 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Grail, Inc. (GRAL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | GRAL | Rank |
|---|---|---|
| Market Cap | $6.23B | 6/26 |
| P/B Ratio | 2.45x | 12/21 |
| EPS | $-9.68 | – |
| Book Value/Share | $56.93 | – |
| Revenue/Share | $3.70 | – |
| FCF/Share | $-6.63 | – |
Profitability & Margins
| Metric | GRAL | Rank |
|---|---|---|
| ROE | -15.4% | 10/14 |
| ROA | -13.8% | 11/18 |
| ROIC | -20.3% | 13/21 |
| Operating Margin | -338.4% | 18/21 |
| Net Margin | -236.9% | 14/16 |
| EBT Margin | -320.4% | 18/21 |
| Tax Rate | 26.0% | – |
Financial Health
| Metric | GRAL | Rank |
|---|---|---|
| Current Ratio | 10.95x | 3/23 |
| D/E Ratio | 0.12x | 16/21 |
| Financial Leverage | 1.12x | 16/21 |
| Working Capital | $831M | 6/23 |
Cash Flow
| Metric | GRAL | Rank |
|---|---|---|
| Operating Cash Flow | -$295M | 24/24 |
| Free Cash Flow | -$296M | 17/17 |
| Capital Spending | -$1M | 5/17 |
| FCF/Sales | -179.2% | 15/16 |
| CapEx/Sales | 0.9% | 15/16 |
Operational Efficiency
| Metric | GRAL | Rank |
|---|---|---|
| Asset Turnover | 0.06x | 15/18 |
| Receivables Turnover | 8.4x | 7/19 |
| Fixed Assets Turnover | 3.7x | 11/17 |
| Days Sales Outstanding | 44 days | 13/19 |
Income Statement
| Metric | GRAL | Rank |
|---|---|---|
| Total Revenue | $165M | 12/19 |
| Operating Income | -$559M | 23/23 |
| Net Income | -$392M | 17/18 |
| R&D Expense | $191M | 3/18 |
| SG&A Expense | $330M | 8/18 |
Dividend & Shareholder Information
| Metric | GRAL | Rank |
|---|---|---|
| Shares Outstanding | 45M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $915M | 32.2% of assets |
| Cash & Short-term Investments | $56M | 2.0% of assets |
| Accounts Receivable | $20M | 0.7% of assets |
| Total Liabilities | $301M | 10.6% of assets |
| Short-term Debt | $76M | 2.7% of assets |
GRAL quarterly financials and insider trading
Grail, Inc. (GRAL) industry peers
Companies classified under the same SEC industry code as Grail, Inc. (Services-Medical Laboratories): 27 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| GRAL Grail, Inc. | $6.23B | |
| NTRA Natera, Inc. | $56.02B | |
| LH Labcorp Holdings Inc. | $28.74B | |
| DGX Quest Diagnostics Inc | $27.18B | |
| GH Guardant Health, Inc. | $23.48B | |
| CAI Caris Life Sciences, Inc. | $9.70B | |
| RDNT Radnet, Inc. | $5.78B | |
| BLLN Billiontoone, Inc. | $5.21B | |
| CDNA Caredx, Inc. | $4.52B | |
| VCYT Veracyte, Inc. | $3.94B | |
| CELC Celcuity Inc. | $3.38B | |
| FTRE Fortrea Holdings Inc. | $2.02B | |
| PSNL Personalis, Inc. | $1.68B | |
| FRNM Freenome, Inc. | $1.23B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.08B | |
| CSTL Castle Biosciences Inc | $1.07B | |
| FLGT Fulgent Genetics, Inc. | $533M | |
| BDSX Biodesix Inc | $222M | |
| XGN Exagen Inc. | $203M | |
| BNR Burning Rock Biotech Ltd | $117M | |
| SERA Sera Prognostics, Inc. | $78M | |
| MDXH Mdxhealth Sa | $18M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $5M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| RNLXY Renalytix Plc | N/A |
Where GRAL sits on the market map
Grail, Inc. (GRAL) stock news
Loading...
Grail, Inc. (GRAL) stock forecast FAQ
What is the Grail, Inc. (GRAL) stock forecast?
Our AI scores Grail, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Grail, Inc. stock predictions?
For GRAL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -45.0%, measured on 254 forecast dates between 2024-08-14 and 2026-08-06 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -24.0%, measured on 296 forecast dates between 2024-08-14 and 2026-10-05. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Grail, Inc. forecasts updated?
Grail, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 4, 2026.
Which companies are Grail, Inc.'s industry peers?
27 issuers in our coverage, GRAL included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.